Pfizer: COVID-19 vaccine booster 80.3% effective in children under 5
Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial involving 1,678 children who received the 3-microgram dose at least two months after the primary vaccine series at a time when the omicron variant was predominating, the company announced today. Pfizer expects to submit the data to the Food and Drug Administration this week for the company’s emergency use application.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…